JP2024540304A5 - - Google Patents

Info

Publication number
JP2024540304A5
JP2024540304A5 JP2024526616A JP2024526616A JP2024540304A5 JP 2024540304 A5 JP2024540304 A5 JP 2024540304A5 JP 2024526616 A JP2024526616 A JP 2024526616A JP 2024526616 A JP2024526616 A JP 2024526616A JP 2024540304 A5 JP2024540304 A5 JP 2024540304A5
Authority
JP
Japan
Prior art keywords
approximately
day
administration
administered
combination according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024526616A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540304A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/060616 external-priority patent/WO2023079494A1/en
Publication of JP2024540304A publication Critical patent/JP2024540304A/ja
Publication of JP2024540304A5 publication Critical patent/JP2024540304A5/ja
Pending legal-status Critical Current

Links

JP2024526616A 2021-11-03 2022-11-03 抗cd38抗体による治療におけるコルチコステロイドの減少 Pending JP2024540304A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163275157P 2021-11-03 2021-11-03
US63/275,157 2021-11-03
US202163280791P 2021-11-18 2021-11-18
US63/280,791 2021-11-18
US202163288785P 2021-12-13 2021-12-13
US63/288,785 2021-12-13
US202263394726P 2022-08-03 2022-08-03
US63/394,726 2022-08-03
PCT/IB2022/060616 WO2023079494A1 (en) 2021-11-03 2022-11-03 Corticosteriod reduction in treatment with anti-cd38 antibodies

Publications (2)

Publication Number Publication Date
JP2024540304A JP2024540304A (ja) 2024-10-31
JP2024540304A5 true JP2024540304A5 (cg-RX-API-DMAC7.html) 2025-11-11

Family

ID=84361138

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024526616A Pending JP2024540304A (ja) 2021-11-03 2022-11-03 抗cd38抗体による治療におけるコルチコステロイドの減少

Country Status (11)

Country Link
US (2) US20230134748A1 (cg-RX-API-DMAC7.html)
EP (1) EP4426435A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024540304A (cg-RX-API-DMAC7.html)
KR (1) KR20240099411A (cg-RX-API-DMAC7.html)
AU (1) AU2022380155A1 (cg-RX-API-DMAC7.html)
CA (1) CA3237175A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001324A1 (cg-RX-API-DMAC7.html)
IL (1) IL312514A (cg-RX-API-DMAC7.html)
JO (1) JOP20240106A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024005406A (cg-RX-API-DMAC7.html)
WO (1) WO2023079494A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4791505A1 (en) * 2023-10-12 2026-08-19 Janssen Biotech, Inc. Methods for treating multiple myeloma comprising an anti-cd38 antibody combined with bortezomib, lenalidomide and dexamethasone

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP2915820A1 (en) 2004-02-06 2015-09-09 MorphoSys AG Anti-CD38 human antibodies and uses therefor
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
CN101287764B (zh) 2005-10-12 2013-11-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
AU2013246443B2 (en) 2012-04-11 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
CA2909952C (en) 2013-04-29 2021-10-12 Teva Pharmaceuticals Australia Pty Ltd. Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
EP3172231B1 (en) 2014-07-24 2021-05-05 Bluebird Bio, Inc. Bcma chimeric antigen receptors
DK3227339T3 (da) 2014-12-05 2022-01-10 Memorial Sloan Kettering Cancer Center Kimæriske antigenreceptorer rettet mod g-protein-koblet receptor og anvendelser deraf
US10383929B2 (en) 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
CR20170526A (es) * 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
TWI811023B (zh) 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途
DE102016211884A1 (de) 2016-06-30 2018-01-04 Zf Friedrichshafen Ag Getriebe für ein Kraftfahrzeug, sowie Antriebsstrang für ein Kraftfahrzeug
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗gprc5d抗體、結合gprc5d與cd3之雙特異性抗原結合分子及其用途
PL3896091T3 (pl) 2016-08-10 2024-04-29 Legend Biotech Ireland Limited Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
EP3820900A1 (en) 2018-07-13 2021-05-19 Genmab A/S Variants of cd38 antibody and uses thereof
MA53920A (fr) * 2018-10-17 2021-09-15 Janssen Biotech Inc Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38
US12077592B2 (en) 2019-01-18 2024-09-03 Janssen Biotech, Inc. GPRC5D chimeric antigen receptors and cells expressing the same
US20200308297A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses

Similar Documents

Publication Publication Date Title
Robinson Medical therapy of inflammatory bowel disease for the 21st century
JP2025102775A5 (cg-RX-API-DMAC7.html)
JP2021534201A5 (cg-RX-API-DMAC7.html)
JP2022538237A5 (cg-RX-API-DMAC7.html)
Marrani et al. Long-term efficacy of abatacept in pediatric patients with idiopathic uveitis: a case series
JP2024518947A5 (cg-RX-API-DMAC7.html)
KR102537990B1 (ko) 스테로이드 용량의 감소 및 염증과 자가면역 질환의 치료를 위한 칸나비디올
JP2024129140A5 (cg-RX-API-DMAC7.html)
JP2019514974A5 (cg-RX-API-DMAC7.html)
JP2024530954A5 (cg-RX-API-DMAC7.html)
JPWO2020250915A5 (cg-RX-API-DMAC7.html)
Jiang et al. Novel use of dupilumab in pemphigus vulgaris and pemphigus foliaceus
Helfer et al. Corticosteroids and adrenal suppression: characterising and avoiding the problem
IL312515A (en) Bispecific cd16a binders
US6096731A (en) Method for preventing tissue damage associated with graft-versus-host or host-versus-graft disease following transplantation
JP2022537555A5 (cg-RX-API-DMAC7.html)
JP2024543509A5 (cg-RX-API-DMAC7.html)
IL312514A (en) Corticosteroid reduction in treatment with anti-cd38 antibodies
WO2020106191A1 (ru) Производное глутаримида для преодоления резистентности к стероидам
JP2024516886A5 (cg-RX-API-DMAC7.html)
JP2021505545A5 (cg-RX-API-DMAC7.html)
JP2024518410A5 (cg-RX-API-DMAC7.html)
JP2024541257A5 (cg-RX-API-DMAC7.html)
JP2024527001A5 (cg-RX-API-DMAC7.html)
Khammissa et al. Glucocorticosteroids in the treatment of immune mediated oral diseases: clinical review